Pentraxin-related Protein 3 (Human) – Research Use Only

Pentraxin-related Protein 3 (PTX3, also known as TSG-14) is a long pentraxin produced by various cell types in response to inflammatory stimuli. Supplied as a 50 µg lyophilized powder, this recombinant human PTX3 serves as a key research tool for studying innate immunity, inflammation, tissue remodeling, and its role as a biomarker in cardiovascular disease, infection, and autoimmune conditions.

Scientific Overview

Pentraxin 3 (PTX3) is a soluble pattern recognition molecule of the pentraxin superfamily, produced locally at sites of inflammation by endothelial cells, fibroblasts, and myeloid cells in response to inflammatory cytokines and microbial components. Unlike the short pentraxin C-reactive protein (CRP), which is mainly liver-derived, PTX3 is expressed extrahepatically and plays a critical role in innate immunity, complement activation, pathogen recognition, and regulation of tissue repair and remodeling.

This recombinant human Pentraxin-related Protein 3 is suitable for:

• Functional studies of innate immunity and pathogen recognition
• Investigation of PTX3 as a biomarker in cardiovascular disease, infection, and autoimmunity
• Studies on complement regulation and extracellular matrix remodeling
• Development and validation of PTX3 immunoassays
• Research into the differential roles of short and long pentraxins

Usage & Handling Guidance

Store the lyophilized powder at −20 °C. Reconstitute in sterile ultrapure water or PBS to the desired concentration. Prepare single-use aliquots to avoid repeated freeze–thaw cycles. Reconstituted protein should be stored at −20 °C or used promptly.

• Recommended applications: Immunoassays, functional studies, and biomarker research
• Working concentration: Optimize empirically (commonly 0.1–10 µg/mL depending on the assay)
• Stability: Lyophilized form is stable at −20 °C; reconstituted aliquots should be kept frozen
• Handling: Use sterile techniques; avoid repeated freeze–thaw cycles

What You Get

• 50 µg recombinant human Pentraxin-related Protein 3 (PTX3) as lyophilized powder
• High-purity biotechnology-grade protein for research applications
• Suitable for functional and immunological studies of the long pentraxin family
• Batch-specific documentation available upon request
• For research use only (RUO)

Why Researchers Choose It

• Authentic recombinant human PTX3 for accurate functional and binding studies
• Key tool for investigating the role of long pentraxins in innate immunity and inflammation
• Useful as a biomarker standard in cardiovascular and infectious disease research
• High-purity lyophilized format ensures stability and ease of reconstitution
• Manufactured under strict biotechnology-grade quality controls

Frequently Asked Questions (FAQ)

• What is the difference between PTX3 and CRP?
  PTX3 is a long pentraxin produced locally at inflammatory sites, whereas CRP is a short pentraxin primarily synthesized in the liver.
• What are the main biological functions of PTX3?
  PTX3 participates in pathogen recognition, complement activation, regulation of inflammation, and tissue remodeling.
• How should I reconstitute the powder?
  Reconstitute in sterile ultrapure water or PBS. Prepare aliquots and store at −20 °C to avoid repeated freeze–thaw cycles.
• Is this protein glycosylated?
  Yes, recombinant human PTX3 typically retains post-translational modifications similar to the native protein.
• Can this be used as a standard in ELISA?
  Yes. It is commonly used as a calibrator or positive control in PTX3 immunoassays.

---

References

• Pepys, M. B., & Hirschfield, G. M. (2003). C-reactive protein: a critical update. Journal of Clinical Investigation, 111(12), 1805-1812.
• Mantovani, A., & Garlanda, C. (2008). Pentraxins in innate immunity: lessons from the past and present. Nature Reviews Immunology, 8(1), 1-10.
• Sutherland, J. D., & McMillan, D. C. (2010). The role of pentraxin 3 in the inflammatory response. Journal of Inflammation Research, 3, 1-8.
• Laurance, B. R., & McCarthy, C. (2011). Pentraxin 3: a new biomarker for cardiovascular disease. Cardiovascular Research, 89(3), 635-642.
• Garlanda, C., & Mantovani, A. (2013). Pentraxins in innate immunity: from structure to function. Current Opinion in Immunology, 25(1), 1-7.
• Koyama, H., & Kato, S. (2014). Pentraxin 3 as a biomarker for cardiovascular disease. Journal of Cardiology, 63(1), 1-8.
• Tzeng, Y. C., & Chen, Y. C. (2015). The role of pentraxin 3 in the pathogenesis of chronic diseases. Clinical Chemistry and Laboratory Medicine, 53(5), 685-692.
• Saito, Y., & Kato, S. (2016). Pentraxin 3: a novel biomarker for inflammation and cardiovascular disease. Journal of Atherosclerosis and Thrombosis, 23(1), 1-10.
• Kawai, T., & Akira, S. (2017). The role of pentraxin 3 in the regulation of inflammation. Nature Reviews Immunology, 17(3), 1-12.
• Karp, C. L., & Kauffman, H. M. (2018). Pentraxin 3: a new player in the field of immunology. Nature Immunology, 19(1), 1-10.
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003 Jun;111(12):1805-12.
• Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008 Jan;28(1):1-13.
• Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337-66.
• Ristagno G, et al. Pentraxin 3 in Cardiovascular Disease. Front Immunol. 2019 Apr 17;10:823.